InterAct Therapeutics (IAT) is a preclinical biotechnology company developing genetic medicines for metastatic cancer. Its core platform is designed specifically to address metastasis by identifying and modulating genes in healthy host tissues that shape metastatic niches and enable tumor survival, immune evasion, and therapeutic resistance. Rather than targeting cancer cells directly, IAT’s approach reprograms the metastatic microenvironment to suppress tumor growth and progression. The platform is modality-agnostic, supporting multiple genetic medicine approaches, and is built for expansion across metastasis-dominant indications. IAT’s first program applies this strategy to breast cancer–derived liver metastases (BC-LM).